Prognostic Potential of Immune Inflammatory Biomarkers in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Immune inflammatory biomarkers are easily obtained and inexpensive blood-based parameters that recently showed prognostic and predictive value in many solid tumors. In this study, we aimed to investigate the role of these biomarkers in predicting distant relapse in breast cancer patients treated wit...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/21/5287 |
| _version_ | 1797468881570234368 |
|---|---|
| author | Marta Truffi Federico Sottotetti Nadav Gafni Sara Albasini Francesca Piccotti Carlo Morasso Valentina Tibollo Michela Mocchi Valentina Zanella Fabio Corsi |
| author_facet | Marta Truffi Federico Sottotetti Nadav Gafni Sara Albasini Francesca Piccotti Carlo Morasso Valentina Tibollo Michela Mocchi Valentina Zanella Fabio Corsi |
| author_sort | Marta Truffi |
| collection | DOAJ |
| description | Immune inflammatory biomarkers are easily obtained and inexpensive blood-based parameters that recently showed prognostic and predictive value in many solid tumors. In this study, we aimed to investigate the role of these biomarkers in predicting distant relapse in breast cancer patients treated with neoadjuvant chemotherapy (NACT). All breast cancer patients who referred to our Breast Unit and underwent NACT were retrospectively reviewed. The pre-treatment neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), and pan-immune-inflammation value (PIV) were calculated from complete blood counts. The primary outcome was 5-year distant-metastasis-free survival (DMFS). In receiver operating characteristic analyses, the optimal cutoff values for the NLR, PLR, MLR, and PIV were determined at 2.25, 152.46, 0.25, and 438.68, respectively. High levels of the MLR, but not the NLR, PLR, or PIV, were associated with improved 5-year DMSF in the study population using both univariate (HR 0.52, <i>p</i> = 0.03) and multivariate analyses (HR, 0.44; <i>p</i> = 0.02). Our study showed that the MLR was a significant independent parameter affecting DMFS in breast cancer patients undergoing NACT. Prospective studies are required to confirm this finding and to define reliable cutoff values, thus leading the way for the clinical application of this biomarker. |
| first_indexed | 2024-03-09T19:12:34Z |
| format | Article |
| id | doaj.art-c89b3bfb4855466b9dc67fb49a6fbecf |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T19:12:34Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-c89b3bfb4855466b9dc67fb49a6fbecf2023-11-24T04:02:03ZengMDPI AGCancers2072-66942022-10-011421528710.3390/cancers14215287Prognostic Potential of Immune Inflammatory Biomarkers in Breast Cancer Patients Treated with Neoadjuvant ChemotherapyMarta Truffi0Federico Sottotetti1Nadav Gafni2Sara Albasini3Francesca Piccotti4Carlo Morasso5Valentina Tibollo6Michela Mocchi7Valentina Zanella8Fabio Corsi9Istituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, ItalyIstituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, ItalyIstituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, ItalyIstituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, ItalyIstituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, ItalyIstituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, ItalyIstituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, ItalyIstituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, ItalyIstituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, ItalyIstituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, ItalyImmune inflammatory biomarkers are easily obtained and inexpensive blood-based parameters that recently showed prognostic and predictive value in many solid tumors. In this study, we aimed to investigate the role of these biomarkers in predicting distant relapse in breast cancer patients treated with neoadjuvant chemotherapy (NACT). All breast cancer patients who referred to our Breast Unit and underwent NACT were retrospectively reviewed. The pre-treatment neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), and pan-immune-inflammation value (PIV) were calculated from complete blood counts. The primary outcome was 5-year distant-metastasis-free survival (DMFS). In receiver operating characteristic analyses, the optimal cutoff values for the NLR, PLR, MLR, and PIV were determined at 2.25, 152.46, 0.25, and 438.68, respectively. High levels of the MLR, but not the NLR, PLR, or PIV, were associated with improved 5-year DMSF in the study population using both univariate (HR 0.52, <i>p</i> = 0.03) and multivariate analyses (HR, 0.44; <i>p</i> = 0.02). Our study showed that the MLR was a significant independent parameter affecting DMFS in breast cancer patients undergoing NACT. Prospective studies are required to confirm this finding and to define reliable cutoff values, thus leading the way for the clinical application of this biomarker.https://www.mdpi.com/2072-6694/14/21/5287inflammatory biomarkersbreast cancer careneoadjuvant chemotherapyblood countprognostic factorstailored therapy |
| spellingShingle | Marta Truffi Federico Sottotetti Nadav Gafni Sara Albasini Francesca Piccotti Carlo Morasso Valentina Tibollo Michela Mocchi Valentina Zanella Fabio Corsi Prognostic Potential of Immune Inflammatory Biomarkers in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Cancers inflammatory biomarkers breast cancer care neoadjuvant chemotherapy blood count prognostic factors tailored therapy |
| title | Prognostic Potential of Immune Inflammatory Biomarkers in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy |
| title_full | Prognostic Potential of Immune Inflammatory Biomarkers in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy |
| title_fullStr | Prognostic Potential of Immune Inflammatory Biomarkers in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy |
| title_full_unstemmed | Prognostic Potential of Immune Inflammatory Biomarkers in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy |
| title_short | Prognostic Potential of Immune Inflammatory Biomarkers in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy |
| title_sort | prognostic potential of immune inflammatory biomarkers in breast cancer patients treated with neoadjuvant chemotherapy |
| topic | inflammatory biomarkers breast cancer care neoadjuvant chemotherapy blood count prognostic factors tailored therapy |
| url | https://www.mdpi.com/2072-6694/14/21/5287 |
| work_keys_str_mv | AT martatruffi prognosticpotentialofimmuneinflammatorybiomarkersinbreastcancerpatientstreatedwithneoadjuvantchemotherapy AT federicosottotetti prognosticpotentialofimmuneinflammatorybiomarkersinbreastcancerpatientstreatedwithneoadjuvantchemotherapy AT nadavgafni prognosticpotentialofimmuneinflammatorybiomarkersinbreastcancerpatientstreatedwithneoadjuvantchemotherapy AT saraalbasini prognosticpotentialofimmuneinflammatorybiomarkersinbreastcancerpatientstreatedwithneoadjuvantchemotherapy AT francescapiccotti prognosticpotentialofimmuneinflammatorybiomarkersinbreastcancerpatientstreatedwithneoadjuvantchemotherapy AT carlomorasso prognosticpotentialofimmuneinflammatorybiomarkersinbreastcancerpatientstreatedwithneoadjuvantchemotherapy AT valentinatibollo prognosticpotentialofimmuneinflammatorybiomarkersinbreastcancerpatientstreatedwithneoadjuvantchemotherapy AT michelamocchi prognosticpotentialofimmuneinflammatorybiomarkersinbreastcancerpatientstreatedwithneoadjuvantchemotherapy AT valentinazanella prognosticpotentialofimmuneinflammatorybiomarkersinbreastcancerpatientstreatedwithneoadjuvantchemotherapy AT fabiocorsi prognosticpotentialofimmuneinflammatorybiomarkersinbreastcancerpatientstreatedwithneoadjuvantchemotherapy |